Evidence map›Paper›PMID 32702298›Full record

Trial reportLancet (London, England)2020

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.

Pedro M Folegatti, Katie J Ewer, Parvinder K Aley, Brian Angus, Stephan Becker, Sandra Belij-Rammerstorfer, Duncan Bellamy, Sagida Bibi, Mustapha Bittaye, Elizabeth A Clutterbuck and 23 more

Erratum issued 6 registry-linked trialsOpen access · bronzeAbstract readClinical Trial, Phase IClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Lancet (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 6 registered trials, which are not on this map. Cited by 1,515 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,515citing papers in PubMed, 1 pooled it
59.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04775069 phase4completednot on this mapstarted 2021, after this paper: background citation

A Prospective Study Comparing the Antibody Response of Subjects With Chronic Liver Disease to mRNA, Inactivated Virus and Adenovirus Vector COVID-19 Vaccines

TypeinterventionalSponsorHumanity & Health Medical Group LimitedRan2021 to 2023Enrolled232ConditionsChronic Liver DiseaseArmsBNT162b2, CoronaVac, AZD1222
NCT04894409 nacompletednot on this map

Evaluation of Silver Nanoparticles as an Oropharyngeal Product (Mouthwash) and Nasal Hygiene, by Health Personnel Working at the Tijuana General Hospital Exposed to Patients Diagnosed With Atypical Pneumonia Caused by SARS-CoV-2

TypeinterventionalSponsorCluster de Bioeconomia de Baja California, A.CRan2020 to 2020Enrolled231ConditionsCoronavirus Disease 2019 (COVID-19)ArmsMouthwash and nose rinse with the AgNPs solution, Mouthwashes and nose rinse in a conventional way
NCT04914832 phase4completednot on this mapstarted 2021, after this paper: background citation

Effectiveness of Covid-19 Vaccination in Eswatini Against SARS-CoV-2 Associated Hospitalization and Death

TypeinterventionalSponsorShabir MadhiRan2021 to 2022Enrolled75,012ConditionsCOVID-19, Pneumonia, ViralArmsAZD1222
NCT04944095 unknown statusnot on this mapstarted 2021, after this paper: background citation

Serology Testing (Antibody Levels) With Time Following SARS-CoV-2 (Covid-19) Vaccinations in Residents of Nursing, Extended Care, and Over-55 Communities

TypeobservationalSponsorDr. Sidney J. StohsRan2021 to 2024Enrolled10,000ConditionsCovid-19, Subjects Vaccinated Against Covid-19ArmsChange in SARS-CoV-2 Antibody Levels
NCT04961385 completednot on this mapstarted 2021, after this paper: background citation

Immunogenicity of the ChAdox1 n CoV-19 Vaccine Against SARS-CoV-2 With 12-dose Vials: an Interim Analysis

TypeobservationalSponsorBangkok Metropolitan Administration Medical College and Vajira HospitalRan2021 to 2021Enrolled60ConditionsCovid19, Vaccine, ImmunogenicityArmsImmunogenicity after first dose of participants who received first dose of ChAdox-1 n COV-19 vaccine
NCT05057936 completednot on this mapstarted 2021, after this paper: background citation

Antibody Response After COVID-19 Vaccination in Chronic Kidney Disease and Kidney Transplant Patients

TypeobservationalSponsorBangkok Metropolitan Administration Medical College and Vajira HospitalRan2021 to 2021Enrolled140ConditionsCovid19, Breakthrough Infection, CKD, Kidney TransplantArmsCOVID vaccine
3 · Its place in the literature

Who cites it

1,515 citing papers in PubMed, 1 synthesis or guideline pooled it, 2,607 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Review
  12. The immunogenicity and safety of adenoviral-based vaccines.Current opinion in allergy and clinical immunology · 2026
    Review
  13. Article
  14. Observational
  15. Article
  16. An adenoviral-vectored vaccine protects mice against aerosol challenge with Yersinia pestis.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  17. Article
  18. Article
  19. Article
  20. Article

1,455 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

33 authors at 10 institutions in 2 countries.

Pedro M FolegattiThe Jenner Institute, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Katie J EwerThe Jenner Institute, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Parvinder K AleyOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Brian AngusNuffield Department of Medicine, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Stephan BeckerInstitute of Virology, Philipps University of Marburg, Marburg, Germany.
Sandra Belij-RammerstorferThe Jenner Institute, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Duncan BellamyThe Jenner Institute, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Sagida BibiOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Mustapha BittayeThe Jenner Institute, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Elizabeth A ClutterbuckOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Christina DoldOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Saul N FaustNIHR Southampton Clinical Research Facility, University Hospital Southampton NHS Foundation Trust and University of Southampton, Southampton, UK.
Adam FinnSchool of Population Health Sciences, University of Bristol, Bristol, UK.
Amy L FlaxmanThe Jenner Institute, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Bassam HallisNational Infection Service, Public Health England, Salisbury, UK.
Paul HeathVaccine Institute, St George's University, London, UK.
Daniel JenkinThe Jenner Institute, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Rajeka LazarusDepartment of Microbiology, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.
Rebecca MakinsonThe Jenner Institute, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Angela M MinassianThe Jenner Institute, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Katrina M PollockNIHR Imperial Clinical Research Facility, Imperial College London, London, UK.
Maheshi RamasamyOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Hannah RobinsonOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Matthew SnapeOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Richard TarrantClinical Biomanufacturing Facility, University of Oxford, Oxford, UK.
Merryn VoyseyOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Catherine GreenClinical Biomanufacturing Facility, University of Oxford, Oxford, UK.
Alexander D DouglasThe Jenner Institute, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Adrian V S HillThe Jenner Institute, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Teresa LambeThe Jenner Institute, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Sarah C GilbertThe Jenner Institute, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Andrew J PollardOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK. Electronic address: andrew.pollard@paediatrics.ox.ac.uk.
Oxford COVID Vaccine Trial Group
University of Oxford · GBOxford BioMedica (United Kingdom) · GBJenner Institute · GBNIHR Imperial Biomedical Research Centre · GBPhilipps University of Marburg · DEPublic Health England · GBSt George's, University of London · GBUniversity Hospitals Bristol and Weston NHS Foundation TrustUniversity Hospital Southampton NHS Foundation Trust · GBUniversity of Bristol · GB

Funding

Medical Research Council MC_PC_19025Medical Research Council MC_PC_19055Medical Research Council MC_PC_19059Medical Research Council MR/T001151/1NIAID NIH HHS HHSN272201400008CWellcome Trust 109965/Z/15/Z
6 · The paper itself

Abstract

backgroundThe pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by vaccination. We assessed the safety, reactogenicity, and immunogenicity of a viral vectored coronavirus vaccine that expresses the spike protein of SARS-CoV-2.

methodsWe did a phase 1/2, single-blind, randomised controlled trial in five trial sites in the UK of a chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19) expressing the SARS-CoV-2 spike protein compared with a meningococcal conjugate vaccine (MenACWY) as control. Healthy adults aged 18-55 years with no history of laboratory confirmed SARS-CoV-2 infection or of COVID-19-like symptoms were randomly assigned (1:1) to receive ChAdOx1 nCoV-19 at a dose of 5 × 10

findingsBetween April 23 and May 21, 2020, 1077 participants were enrolled and assigned to receive either ChAdOx1 nCoV-19 (n=543) or MenACWY (n=534), ten of whom were enrolled in the non-randomised ChAdOx1 nCoV-19 prime-boost group. Local and systemic reactions were more common in the ChAdOx1 nCoV-19 group and many were reduced by use of prophylactic paracetamol, including pain, feeling feverish, chills, muscle ache, headache, and malaise (all p<0·05). There were no serious adverse events related to ChAdOx1 nCoV-19. In the ChAdOx1 nCoV-19 group, spike-specific T-cell responses peaked on day 14 (median 856 spot-forming cells per million peripheral blood mononuclear cells, IQR 493-1802; n=43). Anti-spike IgG responses rose by day 28 (median 157 ELISA units [EU], 96-317; n=127), and were boosted following a second dose (639 EU, 360-792; n=10). Neutralising antibody responses against SARS-CoV-2 were detected in 32 (91%) of 35 participants after a single dose when measured in MNA

interpretationChAdOx1 nCoV-19 showed an acceptable safety profile, and homologous boosting increased antibody responses. These results, together with the induction of both humoral and cellular immune responses, support large-scale evaluation of this candidate vaccine in an ongoing phase 3 programme.

fundingUK Research and Innovation, Coalition for Epidemic Preparedness Innovations, National Institute for Health Research (NIHR), NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and the German Center for Infection Research (DZIF), Partner site Gießen-Marburg-Langen.

Indexed as

Immunogenicity, VaccineAcetaminophenAdenoviruses, SimianAdultAnalgesics, Non-NarcoticAntibodies, NeutralizingAntibodies, ViralBetacoronavirusCoronavirus InfectionsCOVID-19COVID-19 VaccinesFemaleGenetic VectorsHumansImmunization, SecondaryImmunoglobulin GAcetaminophenAnalgesics, Non-NarcoticAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesImmunoglobulin GSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Viral Vaccines

Identifiers

PMID32702298
PMCPMC7445431
OpenAlexW3042833857

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.